Thanks--I'll let the cash burn a hole through my pocket and
spend it on HLCS. I had this in the last contest--but
sequencing has been in the news, so I'll try it again.
There is a nice writeup here:
seekingalpha.com
Boy, when you see a bright kid do a nice writeup, it sure
makes you feel old and stupid <g>.
This might be a good point to be wary about--he writes
Helicos is keeping entirely mum about what I believe to be its Achilles heel ... accuracy.
Still, 454 was bought by Roche and Solexa ended up with
ILMN, so what the heck. Sequenom has been doing well too lately.
Helicos is very thinly traded, up a little today, which is annoying for putting it in the contest.
Here is a recent article worth reading, as I said genomics
is in the news again--it was all the rage five years ago
and so maybe this is an aftershock, heh. Venter again:
technologyreview.com
SNP stocks did well for a time, Orchid, others that
I've forgotten or tried to forget were bought out.
An interesting story I was reminded of today was Genaissance,
which ended up at CLDA. Clinical Data is one I ought
to have stayed with instead of batting at groundhogs
(I owned gnsc for a time). |
